STOCK TITAN

Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Anixa Biosciences (NASDAQ: ANIX) will work with Curia to develop the final formulation of its investigational breast cancer vaccine for a Phase 2 trial. Curia will help develop a formulation designed to improve stability and consistency and be suitable for clinical manufacturing. Anixa is developing the vaccine with Cleveland Clinic and intends the formulation work to support future studies and potential commercial production.

The Phase 1 trial met its primary endpoints in a study involving 35 women and showed a favorable safety and tolerability profile. 74% of participants showed immune responses as defined by the trial protocol. The vaccine is designed to help the immune system recognize alpha-lactalbumin, a protein expressed in many breast cancers. Anixa is preparing for Phase 2 to further evaluate potential clinical benefits.

Loading...
Loading translation...
4 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointPhase 1 trial met its primary endpoints in a study involving 35 women
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Curia collaboration will support final formulation development for Phase 2 and potential commercial production
  • Minor pointProtocol-defined immune responses occurred in 74% of Phase 1 participants
  • Minor pointPhase 1 safety and tolerability showed a favorable profile

Negative

  • None.

Key Figures

Phase 1 participants: 35 women Protocol-defined immune responses: 74%
Phase 1 participants
35 women
Breast cancer vaccine trial
Protocol-defined immune responses
74%
Phase 1 breast cancer vaccine trial participants

Key Terms

cdmo, primary endpoints, alpha-lactalbumin, aseptic manufacturing
4 terms
cdmo technical
"contract development and manufacturing organization (CDMO)"
A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.
primary endpoints medical
"meeting its primary endpoints"
Primary endpoints are the main, predefined measures a clinical trial uses to judge whether a treatment works, such as whether patients live longer or symptoms improve by a certain amount. They are the trial’s chief “scoreboard” subjects are measured against, and meeting or missing them strongly influences regulatory approval, market expectations and a drug’s commercial value—so investors watch them as a direct signal of risk and potential reward.
alpha-lactalbumin medical
"recognize alpha-lactalbumin, a protein expressed in many breast cancers"
Alpha-lactalbumin is a protein naturally found in mammalian milk that helps produce lactose (milk sugar) and supplies key amino acids, notably tryptophan. Investors care because it is used as an ingredient in infant formulas, medical nutrition and dietary supplements, and can affect product claims, manufacturing costs and regulatory review—think of it as a specialty ingredient that can change a food or drug product’s nutritional value and market appeal.
aseptic manufacturing technical
"the requirements of aseptic manufacturing"
Aseptic manufacturing is the process of producing sterile pharmaceutical and biological products in controlled environments designed to prevent microbial or particulate contamination. It relies on cleanrooms, filtered air, sterile equipment and strict procedures to keep product sterile from production through final packaging—like baking in a sealed, germ-free oven rather than trying to sterilize afterward. It matters to investors because contamination, regulatory problems or production stoppages tied to aseptic failures can cause batch losses, recalls and costly downtime that affect revenue and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Collaboration to support development of a stable, scalable formulation for clinical development and potential commercialization

SAN JOSE, Calif., Nov. 18, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will work with Curia, a leading global contract development and manufacturing organization (CDMO), to provide formulation development services for Anixa's investigational breast cancer vaccine in preparation for its upcoming Phase 2 clinical trial. The vaccine is being developed in collaboration with Cleveland Clinic.

Anixa Biosciences, Inc.

Under the collaboration, Curia will support the development of a formulation designed to optimize the vaccine's stability, consistency, and suitability for clinical manufacturing. This work represents an important step in Anixa's preparations for Phase 2 and is intended to establish a formulation and development process capable of supporting future clinical studies and potential commercial production.

"Selection of Curia is another important milestone as we prepare to advance our breast cancer vaccine into Phase 2 clinical development," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "Our Phase 1 trial demonstrated encouraging safety and immune-response results, and we are now focused on the activities necessary to support the next stage of clinical testing. Curia brings extensive expertise in pharmaceutical formulation and manufacturing processes, and we believe their capabilities will be valuable as we work toward developing a vaccine that could ultimately help prevent breast cancer."

"Curia looks forward to providing formulation development support for Anixa's peptide cancer vaccine," said Ranald Baillie, VP, Drug Product Development and General Manager at Curia Glasgow. "Successful formulation and product development requires looking beyond the formulation itself to understand stability, analytical performance, scalability and the requirements of aseptic manufacturing. Curia's integrated expertise allows us to address those considerations early and develop robust processes designed to support Anixa as it advances this vaccine towards commercialization."

Anixa's investigational breast cancer vaccine is designed to stimulate the immune system to recognize alpha-lactalbumin, a protein expressed in many breast cancers. The vaccine recently completed a Phase 1 clinical trial involving 35 women, meeting its primary endpoints and demonstrating a favorable safety and tolerability profile, with 74% of participants exhibiting protocol-defined immune responses. Anixa is preparing to advance the vaccine into Phase 2 clinical development to further evaluate its potential clinical benefits.

About Curia
Curia is a global contract development and manufacturing organization with more than 30 years of experience supporting pharmaceutical and biotechnology companies through drug discovery, development, and manufacturing. With an extensive global network of facilities, Curia provides integrated services spanning formulation development, analytical testing, process development, clinical manufacturing, and commercial production. Its Glasgow, Scotland facility specializes in sterile drug product development and manufacturing, including complex formulations, stability testing, lyophilization, and aseptic processing. For more information, visit www.curiaglobal.com.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-and-curia-will-develop-final-formulation-for-breast-cancer-vaccine-in-preparation-for-phase-2-clinical-trial-302943033.html

SOURCE Anixa Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Curia do for Anixa Biosciences’ Phase 2 breast cancer vaccine trial?

Curia will help develop the vaccine’s final formulation in preparation for Phase 2. The work is intended to improve stability and consistency and support manufacturing for clinical studies and potential commercial production.

What did Anixa Biosciences’ Phase 1 breast cancer vaccine trial show?

Anixa’s Phase 1 trial met its primary endpoints and showed favorable safety and tolerability. The trial involved 35 women, and 74% of participants showed an immune response as defined by the trial protocol.

Keep reading